GAS6 and nonpapillary renal cell carcinoma: Inhibitors of AXL, when used in conjunction with antiangiogenic agents, have shown a significant reduction in vessel or tube formation in renal carcinoma xenografts.102 In addition, the GAS6/AXL/S100A10 axis has been found to promote plasmin generation, endothelial cell migration, and angiogenesis in clear cell renal cell carcinoma (ccRCC) cells, with AXL expression being associated with resistance to antiangiogenic therapies.102